Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vudalimab plus chemotherapy versus pembrolizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer
NL-OMON60230Phase 2Completed
- Sponsor
- Xencor
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vudalimab and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Xencor. Primary endpoints: Incidence of treatment-emergent adverse events and Progression-free survival. Started Jun 2024; status: completed.
02
Drugs
vudalimabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60230.